Press Releases

View the latest press releases and important announcements from CNO.

CNO Financial Group Reports Second Quarter 2019 Results
Solid operating income
Fourth consecutive quarter of premium growth in all businesses

CARMEL, Ind., July 30, 2019 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE: CNO) today announced that for the quarter ending June 30, 2019, net income was $0.24 per diluted share, compared to $0.61 per diluted share in 2Q18.  CNO also reported that 2Q19 net operating income (1) was $0.48 per diluted share, compared to $0.46 in 2Q18 (as adjusted to remove the earnings from the long-term care business that was ceded in 3Q18).

"Leveraging our multiple distribution channels, CNO delivered its fourth consecutive quarter of growth with solid production across each of our businesses and product lines," said Gary C. Bhojwani, chief executive officer. "We continued to use excess capital to repurchase shares, which drove an increase in operating earnings per share, adjusting for the long-term care business that was ceded in the third quarter of 2018, and contributed to higher operating return on equity."

Highlights

  • Annuity collected premiums were up 19% from 2Q18
  • First-year collected premiums were up 14% from 2Q18
  • Life and health sales were up 4% from 2Q18
  • All benefit ratios were within provided guidance
  • Returned $72.4 million to shareholders in the form of share repurchases ($55.0 million) and dividends ($17.4 million)

Quarterly Operating Results


Three months ended



June 30,



2019


2018



(Dollars in millions,
except per share data)


Net operating income (1)

$

76.4



$

81.9



Net realized investment gains (losses) from sales and impairments (net of related
amortization)

(1.7)



10.9



Net change in market value of investments recognized in earnings

6.8



(.3)



Fair value changes in embedded derivative liabilities (net of related amortization)

(35.9)



8.3



Fair value changes related to agent deferred compensation plan

(11.6)



11.0



Loss on extinguishment of debt

(7.3)





Other

.7



(4.2)



Non-operating income (loss) before taxes

(49.0)



25.7



Income tax expense (benefit) on non-operating income

(10.2)



5.4



Net non-operating income (loss)

(38.8)



20.3



Net income

$

37.6



$

102.2








Per diluted share:





Net operating income

$

.48



$

.49



Net realized investment gains (losses) from sales and impairments (net of
related amortization and taxes)

(.01)



.05



Net change in market value of investments recognized in earnings (net of taxes)

.04





Fair value changes in embedded derivative liabilities (net of related
amortization and taxes)

(.18)



.04



Fair value changes related to agent deferred compensation plan (net of taxes)

(.06)



.05



Loss on extinguishment of debt (net of taxes)

(.03)





Other



(.02)



Net income

$

.24



$

.61



 

Please refer to our 2Q2019 Quarterly Financial Supplement for additional information related to the Company's financial and reporting results for the quarter ended June 30, 2019.  Such information was furnished as an exhibit to our Current Report on Form 8-K dated July 30, 2019.

Significant Items Impacting Net Operating Income


Three months ended


June 30,


2019


2018


Dollars in


Per diluted


Dollars in


Per diluted


millions


share


millions


share

Net operating income (1)

$

76.4



$

.48



$

81.9



$

.49


Earnings on long-term care ceded block





(4.2)



(.03)


Net operating earnings, excluding the earnings on the long-
term care ceded block

$

76.4



$

.48



$

77.7



$

.46


 

In 3Q18, we ceded the Bankers Life legacy long-term care business under a 100% indemnity coinsurance agreement.  In the above table, we have adjusted the operating earnings in 2Q18 to remove the earnings of this block.

There were no other significant items in 2Q19 or 2Q18.

Non-Operating Items
Net realized investment gains (losses) (net of related amortization) in 2Q19 and 2Q18 were $(1.7) million and $10.9 million, respectively.  There were no other-than-temporary impairment losses recognized in 2Q19 or 2Q18.

During 2Q19 and 2Q18, we recognized an increase (decrease) in earnings of $6.8 million and $(.3) million, respectively, due to the net change in market value of investments recognized in earnings.

During 2Q19 and 2Q18, we recognized an increase (decrease) in earnings of $(35.9) million and $8.3 million, respectively, resulting from changes in the estimated fair value of embedded derivative liabilities related to our fixed index annuities, net of related amortization.  Such amounts include the impacts of changes in market interest rates used to determine the derivative's estimated fair value.

In 2Q19 and 2Q18, we recognized an increase (decrease) in earnings of $(11.6) million and $11.0 million, respectively, for the mark-to-market change in the agent deferred compensation plan liability which was impacted by changes in the underlying actuarial assumptions used to value the liability.  We recognize the mark-to-market change in the estimated value of this liability through earnings as assumptions change.

The results for 2Q19 include a $7.3 million loss on the extinguishment of debt related to the completion of our previously announced debt refinancing transaction.

Statutory (based on non-GAAP measures) and GAAP Capital Information
Our consolidated statutory risk-based capital ratio was estimated at 409% at June 30, 2019, reflecting estimated 2Q19 statutory operating income of $79 million (and $162 million in the first six months of 2019) and the payment of insurance company dividends to the holding company of $89.9 million during 2Q19 and $130.9 million during the first six months of 2019.

During the second quarter of 2019, we repurchased $55.0 million of common stock under our securities repurchase program (including $2.0 million of repurchases settled in 3Q19).  We repurchased 3.3 million common shares at an average cost of $16.46 per share.  As of June 30, 2019, we had 156.8 million shares outstanding and had authority to repurchase up to an additional $182.6 million of our common stock.  During 2Q19, dividends paid on common stock totaled $17.4 million.

Unrestricted cash and investments held by our holding company were $264 million at June 30, 2019, compared to $220 million at December 31, 2018.

Book value per common share was $27.12 and $20.78 at June 30, 2019 and December 31, 2018, respectively.  Book value per diluted share, excluding accumulated other comprehensive income (loss) (2), was $20.00 at June 30, 2019, compared to $19.52 at December 31, 2018.

The debt-to-capital ratio was 18.9 percent and 21.4 percent at June 30, 2019 and December 31, 2018, respectively.  Our debt-to-total capital ratio, excluding accumulated other comprehensive income (3) was 23.9 percent at June 30, 2019 compared to 22.3 percent at December 31, 2018.

Return on equity for the trailing four quarters ended June 30, 2019 and 2018, was (10.9)% and 4.6%, respectively.  Return on equity for the trailing four quarters ended June 30, 2019 was unfavorably impacted by a loss of $661.1 million recognized in the third quarter of 2018 related to a long-term care reinsurance transaction.  Operating return, excluding significant items, on equity, excluding accumulated other comprehensive income and net operating loss carryforwards (7) for the trailing four quarters ended June 30, 2019 and 2018, was 10.9% and 9.4%, respectively.

Conference Call
The Company will host a conference call to discuss results on July 31, 2019 at 11:00 a.m. Eastern Daylight Time. During the call, we will be referring to a presentation that will be available at the Investors section of the company's website this evening.

To participate by dial-in, please dial (844) 668-8093 or (647) 253-8656 for international participants, at least five minutes before the call start time. The operator will ask you to identify yourself and your company, and will also ask for the conference ID, "9687346."

For those investors who prefer to listen to the call online, we will be broadcasting the call live via webcast.  The event can be accessed through the Investors section of our website as follows:  (http://ir.cnoinc.com).  Listeners should go to the website at least 15 minutes before the event to register, download and install any necessary software.

If you are unable to join us on the call, you may access a replay of the call through webcast,  available through the Investors section of our website at: (http://ir.cnoinc.com).

About CNO Financial Group
CNO Financial Group, Inc. (NYSE: CNO) is a holding company.  Our insurance companies - principally Bankers Life and Casualty Company, Colonial Penn Life Insurance Company and Washington National Insurance Company - primarily serve middle-income pre-retiree and retired Americans by helping them protect against financial adversity and provide for a more secure retirement.  For more information, visit CNO online at www.CNOinc.com.

 

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEET

(Dollars in millions)

(unaudited)




June 30,
 2019


December 31,
2018

ASSETS




Investments:




Fixed maturities, available for sale, at fair value (amortized cost: June 30, 2019 -
$18,773.1; December 31, 2018 - $18,107.8)

$

20,437.2



$

18,447.7


Equity securities at fair value (cost: June 30, 2019 - $39.9; December 31, 2018 -
$319.8)

38.8



291.0


Mortgage loans

1,596.5



1,602.1


Policy loans

121.6



119.7


Trading securities

248.3



233.1


Investments held by variable interest entities

1,215.2



1,468.4


Other invested assets

1,018.8



833.4


Total investments

24,676.4



22,995.4


Cash and cash equivalents - unrestricted

557.4



594.2


Cash and cash equivalents held by variable interest entities

50.5



62.4


Accrued investment income

211.2



205.2


Present value of future profits

299.3



343.6


Deferred acquisition costs

1,253.2



1,322.5


Reinsurance receivables

4,829.4



4,925.4


Income tax assets, net

348.3



630.0


Assets held in separate accounts

4.9



4.4


Other assets

485.4



356.7


Total assets

$

32,716.0



$

31,439.8


LIABILITIES AND SHAREHOLDERS' EQUITY




Liabilities:




Liabilities for insurance products:




Policyholder account balances

$

11,758.5



$

11,594.1


Future policy benefits

11,407.2



11,082.4


Liability for policy and contract claims

517.8



521.9


Unearned and advanced premiums

248.1



253.9


Liabilities related to separate accounts

4.9



4.4


Other liabilities

740.2



632.4


Investment borrowings

1,645.2



1,645.8


Borrowings related to variable interest entities

1,153.6



1,417.2


Notes payable – direct corporate obligations

988.3



916.8


Total liabilities

28,463.8



28,068.9


Commitments and Contingencies




Shareholders' equity:




Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued
and outstanding: June 30, 2019 – 156,768,002; December 31, 2018 –
162,201,692)

1.6



1.6


Additional paid-in capital

2,903.2



2,995.0


Accumulated other comprehensive income

1,098.2



177.7


Retained earnings

249.2



196.6


Total shareholders' equity

4,252.2



3,370.9


Total liabilities and shareholders' equity

$

32,716.0



$

31,439.8


 

 

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF OPERATIONS

(Dollars in millions, except per share data)

(unaudited)




Three months ended


Six months ended


June 30,


June 30,


2019


2018


2019


2018

Revenues:








Insurance policy income

$

618.3



$

659.8



$

1,237.6



$

1,319.7


Net investment income:








General account assets

286.7



328.2



557.3



657.3


Policyholder and other special-purpose portfolios

47.8



35.7



133.0



48.5


Realized investment gains (losses):








Net realized investment gains (losses), excluding
impairment losses

5.3



11.0



23.6



(4.2)


Impairment losses recognized (a)





(2.2)




Total realized gains

5.3



11.0



21.4



(4.2)


Fee revenue and other income

21.7



11.6



53.5



32.8


Total revenues

979.8



1,046.3



2,002.8



2,054.1


Benefits and expenses:








Insurance policy benefits

610.4



618.2



1,233.9



1,204.8


Interest expense

38.6



37.7



79.6



71.3


Amortization

46.2



61.0



104.4



132.9


Loss on extinguishment of debt

7.3





7.3




Loss on extinguishment of borrowings related to variable
interest entities



3.8





3.8


Other operating costs and expenses

229.6



195.8



464.3



403.4


Total benefits and expenses

932.1



916.5



1,889.5



1,816.2


Income before income taxes

47.7



129.8



113.3



237.9


Income tax expense on period income

10.1



27.6



23.9



51.4


Net income

$

37.6



$

102.2



$

89.4



$

186.5


Earnings per common share:








Basic:








Weighted average shares outstanding

158,816,000



166,098,000



159,882,000



166,579,000


Net income

$

.24



$

.62



$

.56



$

1.12


Diluted:








Weighted average shares outstanding

159,735,000



167,978,000



160,962,000



168,828,000


Net income

$

.24



$

.61



$

.56



$

1.10



______________

(a)

No portion of the other-than-temporary impairments recognized in the periods was included in accumulated other comprehensive income.

 

 

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

OPERATING RESULTS




Six months ended


June 30,


2019


2018


(Dollars in millions,
except per share data)

Net operating income (1)

$

142.2



$

155.8


Net realized investment gains (losses) from sales and impairments (net of related
amortization)

(2.4)



11.4


Net change in market value of investments recognized in earnings

23.4



(16.0)


Fair value changes in embedded derivative liabilities (net of related amortization)

(65.5)



33.4


Fair value changes related to agent deferred compensation plan

(16.9)



11.0


Loss on extinguishment of debt

(7.3)




Other

1.9



(.9)


Non-operating income (loss) before taxes

(66.8)



38.9


Income tax expense (benefit) on non-operating income

(14.0)



8.2


Net non-operating income (loss)

(52.8)



30.7


Net income

$

89.4



$

186.5






Per diluted share:




Net operating income

$

.89



$

.92


Net realized investment gains (losses) from sales and impairments (net of
related amortization and taxes)

(.01)



.05


Net change in market value of investments recognized in earnings (net of taxes)

.11



(.07)


Fair value changes in embedded derivative liabilities (net of related
amortization and taxes)

(.32)



.16


Fair value changes related to agent deferred compensation plan (net of taxes)

(.08)



.05


Loss on extinguishment of debt (net of taxes)

(.04)




Other

.01



(.01)


Net income

$

.56



$

1.10


 

 

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

FIRST-YEAR COLLECTED PREMIUMS

(Dollars in millions)




Three months ended


June 30,


2019


2018

Bankers Life:




Medicare supplement

$

14.9



$

15.5


Long-term care

4.7



3.7


Supplemental health

1.1



1.1


Other health

.1



.2


Life

28.7



31.8


Annuity

339.4



286.0


Total

388.9



338.3


Washington National:




Supplemental health and other health

16.8



17.8


Life

2.2



1.6


Total

19.0



19.4


Colonial Penn:




Life

13.1



11.3


Total

13.1



11.3


Total first-year collected premiums from segments

$

421.0



$

369.0




TOTAL COLLECTED PREMIUMS

(Dollars in millions)




Three months ended


June 30,


2019


2018

Bankers Life:




Medicare supplement

$

176.6



$

176.8


Long-term care

63.1



63.7


Supplemental health

6.2



5.9


Other health

1.4



1.5


Life

116.9



118.5


Annuity

341.0



287.0


Total

705.2



653.4


Washington National:




Supplemental health and other health

157.3



152.5


Medicare supplement

10.1



11.5


Life

9.3



8.4


Annuity

.2



.4


Total

176.9



172.8


Colonial Penn:




Life

76.3



73.4


Medicare supplement and other health

.4



.4


Total

76.7



73.8


Long-term care in run-off:




Long-term care

3.4



47.6


Total

3.4



47.6


Total collected premiums from segments

$

962.2



$

947.6


 

 

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

NEW ANNUALIZED PREMIUMS FOR LIFE AND HEALTH PRODUCTS (4)

(Dollars in millions)




Three months ended


June 30,


2019


2018

Bankers Life:




Medicare supplement

$

14.5



$

14.3


Long-term care

6.4



5.3


Supplemental health and other health

1.4



1.4


Life

17.1



17.9


Total

39.4



38.9


Washington National:




Supplemental health

23.5



23.9


Life

2.7



2.1


Total

26.2



26.0


Colonial Penn:




Life

19.6



16.9


Total

19.6



16.9


Total new annualized premiums

$

85.2



$

81.8




ANNUITY ACCOUNT VALUES

(Dollars in millions)




June 30,


2019


2018

Bankers Life

$

8,812.3



$

8,325.9


Washington National

320.4



358.2


Total

$

9,132.7



$

8,684.1




BROKER DEALER AND REGISTERED INVESTMENT ADVISOR CLIENT ASSETS

(Dollars in millions)




Three months ended


June 30,


2019


2018

Net new client assets (a):




Brokerage

$

5.1



$

3.1


Advisory

33.2



49.1


Total

$

38.3



$

52.2


Client assets at end of period (b):




Brokerage

$

886.0



$

813.6


Advisory

417.0



268.1


Total

$

1,303.0



$

1,081.7




(a)

Net new client assets includes total inflows of cash and securities into brokerage and managed advisory accounts less outflows. Inflows include interest and dividends and exclude changes due to market fluctuations.

(b)

Client assets include cash and securities in brokerage and managed advisory accounts.


Bankers Life is the marketing brand of various affiliated companies of CNO Financial Group including, Bankers Life and Casualty Company, Bankers Life Securities, Inc., and Bankers Life Advisory Services, Inc. Non-affiliated insurance products are offered through Bankers Life General Agency, Inc. (dba BL General Insurance Agency, Inc., AK, AL, CA, NV, PA). Agents who are financial advisors are registered with Bankers Life Securities, Inc.


Securities and variable annuity products and services are offered by Bankers Life Securities, Inc. Member FINRA/SIPC, (dba BL Securities, Inc., AL, GA, IA, IL, MI, NV, PA). Advisory products and services are offered by Bankers Life Advisory Services, Inc. SEC Registered Investment Adviser (dba BL Advisory Services, Inc., AL, GA, IA, MT, NV, PA). Home Office: 111 East Wacker Drive, Suite 1900, Chicago, IL 60601.

 

 

Benefit Ratios On Major Health Lines Of Business




Three months ended


June 30,


2019


2018

Bankers Life:




Medicare supplement:




Earned premium

$191 million


$192 million

Benefit ratio (5)

74.0%


73.1%

Long-term care:




Earned premium

$64 million


$64 million

Benefit ratio (5)

122.1%


119.3%

Interest-adjusted benefit ratio (a non-GAAP measure) (6)

77.5%


76.3%

Washington National:




Supplemental health:




Earned premium

$157 million


$152 million

Benefit ratio (5)

80.2%


80.7%

Interest-adjusted benefit ratio (a non-GAAP measure) (6)

56.2%


56.6%

 

NOTES


(1)

Management believes that an analysis of Net income applicable to common stock before: (i) net realized investment gains or losses from sales and impairments, net of related amortization and taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) fair value changes due to fluctuations in the interest rates used to discount embedded derivative liabilities related to our fixed index annuities, net of related amortization and taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transaction, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to variable interest entities, net of taxes ("Net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry.  Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the company's underlying fundamentals.  A reconciliation of Net operating income to Net income applicable to common stock is provided in the tables on pages 2 and 7.  Additional information concerning this non-GAAP measure is included in our periodic filings with the Securities and Exchange Commission that are available in the "Investors - SEC Filings" section of CNO's website, www.CNOinc.com.



(2)

Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised, restricted stock and performance units were vested and convertible securities were converted.  The dilution from options, restricted shares and performance units is calculated using the treasury stock method.  Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period.  The dilution from convertible securities is calculated assuming the securities were converted on the last day of the period.  In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure.  Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.



(3)

The calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure.  Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.



(4)

Measured by new annualized premium for life and health products, which includes 10% of single premium whole life deposits and 100% of all other premiums (excluding annuities).  Medicare Advantage sales are not comparable to other sales and are therefore excluded in all periods.



(5)

The benefit ratio is calculated by dividing the related product's insurance policy benefits by insurance policy income.



(6)

The interest-adjusted benefit ratio (a non-GAAP measure) is calculated by dividing the product's insurance policy benefits less imputed interest income on the accumulated assets backing the insurance liabilities by insurance policy income.  Interest income is an important factor in measuring the performance of longer duration health products.  The net cash flows generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases), which will be paid out as benefits in later policy years (accounted for as reserve decreases).  Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in the change in reserve will be partially offset by the imputed interest income earned on the accumulated assets.  The interest-adjusted benefit ratio reflects the effects of such interest income offset (which is equal to the tabular interest on the related insurance liabilities).  Since interest income is an important factor in measuring the performance of these products, management believes a benefit ratio, which includes the effect of interest income, is useful in analyzing product performance.  Additional information concerning this non-GAAP measure is included in our periodic filings with the Securities and Exchange Commission that are available in the "Investors - SEC Filings" section of CNO Financial's website, www.CNOinc.com.



(7)

The following summarizes the calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); and (iii) return on equity are as follows (dollars in millions):









Trailing twelve months ended





2Q19


2Q18


Net operating income

$

289.5


$

318.3









Net operating income, excluding significant items

$

304.6


$

309.0









Net income (loss)

$

(412.1)


$

216.4









Average common equity, excluding accumulated other





          comprehensive income (loss) and net operating loss





          carryforwards (a non-GAAP financial measure)

$

2,782.7


$

3,298.5









Average common shareholders' equity

$

3,795.6


$

4,740.9









Operating return on equity, excluding accumulated other





          comprehensive income (loss) and net operating loss





          carryforwards (a non-GAAP financial measure)

10.4%


9.6%









Operating return, excluding significant items, on equity, excluding





          accumulated other comprehensive income (loss) and net





          operating loss carryforwards (a non-GAAP financial measure)

10.9%


9.4%









Return on equity

(10.9)%


4.6%

 

 

The following summarizes: (i) operating earnings; (ii) significant items; (iii) operating earnings, excluding significant items; and (iv) net income(loss) (dollars in millions):










Net operating











Net operating


income,











income,


excluding




Net







excluding


significant




income (loss) -



Net operating


Significant


significant


items - trailing


Net


trailing



income


items (a)


items


four quarters


income (loss)


four quarters

3Q17


$

76.7



$

(2.0)



$

74.7



$

269.7



$

100.8



$

480.7


4Q17


85.8



(6.4)



79.4



288.3



(70.9)



175.6


1Q18


73.9



(.9)



73.0



299.6



84.3



197.6


2Q18


81.9





81.9



309.0



102.2



216.4


3Q18


87.5





87.5



321.8



(529.8)



(414.2)


4Q18


59.8



15.1



74.9



317.3



28.3



(315.0)


1Q19


65.8





65.8



310.1



51.8



(347.5)


2Q19


76.4





76.4



304.6



37.6



(412.1)



(a) The significant items have been discussed in prior press releases.
















 

 

A reconciliation of pretax operating earnings (a non-GAAP financial measure) to net income (loss) is as follows (dollars in millions):






Twelve months ended




2Q19


2Q18

Pretax operating earnings (a non-GAAP financial measure)

$

362.3



$

439.7


Income tax (expense) benefit

(72.8)



(121.4)


Net operating income

289.5



318.3


Non-operating items:




Net realized investment gains (losses) from sales and impairments, net of related
amortization

24.1



34.7


Net change in market value of investments recognized in earnings

(9.4)



(12.8)


Fair value changes in embedded derivative liabilities, net of related amortization

(43.4)



41.2


Fair value changes and amendment related to the agent deferred compensation plan

(16.0)



(1.2)


Loss on extinguishment of debt

(7.3)




Loss on reinsurance transaction

(704.2)




Other

4.5



(8.4)


Non-operating income (loss) before taxes

(751.7)



53.5


Income tax expense (benefit):




    On non-operating income (loss)

(157.9)



13.3


    Valuation allowance for deferred tax assets and other tax items

107.8



142.1


Net non-operating income (loss)

(701.6)



(101.9)


Net income (loss)

$

(412.1)



$

216.4








 

 

A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders' equity, is as follows (dollars in millions):






1Q17


2Q17


3Q17


4Q17

Consolidated capital, excluding accumulated other comprehensive








          income (loss) and net operating loss carryforwards








          (a non-GAAP financial measure)

$

3,236.6



$

3,263.2



$

3,335.0



$

3,225.6


Net operating loss carryforwards

640.6



621.6



613.1



409.8


Accumulated other comprehensive income

729.6



894.5



933.6



1,212.1


Common shareholders' equity

$

4,606.8



$

4,779.3



$

4,881.7



$

4,847.5















1Q18


2Q18


3Q18


4Q18

Consolidated capital, excluding accumulated other comprehensive








          income (loss) and net operating loss carryforwards








          (a non-GAAP financial measure)

$

3,318.7



$

3,366.0



$

2,705.8



$

2,687.3


Net operating loss carryforwards

404.2



388.7



510.6



505.9


Accumulated other comprehensive income

894.3



700.2



403.5



177.7


Common shareholders' equity

$

4,617.2



$

4,454.9



$

3,619.9



$

3,370.9















1Q19


2Q19





Consolidated capital, excluding accumulated other comprehensive








          income (loss) and net operating loss carryforwards








          (a non-GAAP financial measure)

$

2,703.4



$

2,702.9






Net operating loss carryforwards

479.6



451.1






Accumulated other comprehensive income

654.9



1,098.2






Common shareholders' equity

$

3,837.9



$

4,252.2
















 

 

A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders' equity, is as follows (dollars in millions):






Trailing four quarter average




2Q19


2Q18

Consolidated capital, excluding accumulated other comprehensive




          income (loss) and net operating loss carryforwards




          (a non-GAAP financial measure)

$

2,782.7



$

3,298.5


Net operating loss carryforwards

479.0



483.1


Accumulated other comprehensive income

533.8



959.3


Common shareholders' equity

$

3,795.5



$

4,740.9


 

Cautionary Statement Regarding Forward-Looking Statements.  Our statements, trend analyses and other information contained in this press release relative to markets for CNO Financial's products and trends in CNO Financial's operations or financial results, as well as other statements, contain forward-looking statements within the meaning of the federal securities laws and the Private Securities Litigation Reform Act of 1995.  Forward-looking statements typically are identified by the use of terms such as "anticipate," "believe," "plan," "estimate," "expect," "project," "intend," "may," "will," "would," "contemplate," "possible," "attempt," "seek," "should," "could," "goal," "target," "on track," "comfortable with," "optimistic," "guidance," "outlook" and similar words, although some forward-looking statements are expressed differently. You should consider statements that contain these words carefully because they describe our expectations, plans, strategies and goals and our beliefs concerning future business conditions, our results of operations, financial position, and our business outlook or they state other ''forward-looking'' information based on currently available information. Assumptions and other important factors that could cause our actual results to differ materially from those anticipated in our forward-looking statements include, among other things: (i) changes in or sustained low interest rates causing reductions in investment income, the margins of our fixed annuity and life insurance businesses, and sales of, and demand for, our products; (ii) expectations of lower future investment earnings may cause us to accelerate amortization, write down the balance of insurance acquisition costs or establish additional liabilities for insurance products; (iii) general economic, market and political conditions and uncertainties, including the performance and fluctuations of the financial markets which may affect the value of our investments as well as our ability to raise capital or refinance existing indebtedness and the cost of doing so; (iv) the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject; (v) our ability to make anticipated changes to certain non-guaranteed elements of our life insurance products; (vi) our ability to obtain adequate and timely rate increases on our health products, including our long-term care business; (vii) the receipt of any required regulatory approvals for dividend and surplus debenture interest payments from our insurance subsidiaries; (viii) mortality, morbidity, the increased cost and usage of health care services, persistency, the adequacy of our previous reserve estimates, changes in the health care market and other factors which may affect the profitability of our insurance products; (ix) changes in our assumptions related to deferred acquisition costs or the present value of future profits; (x) the recoverability of our deferred tax assets and the effect of potential ownership changes and tax rate changes on their value; (xi) our assumption that the positions we take on our tax return filings will not be successfully challenged by the Internal Revenue Service; (xii) changes in accounting principles and the interpretation thereof; (xiii) our ability to continue to satisfy the financial ratio and balance requirements and other covenants of our debt agreements; (xiv) our ability to achieve anticipated expense reductions and levels of operational efficiencies including improvements in claims adjudication and continued automation and rationalization of operating systems; (xv) performance and valuation of our investments, including the impact of realized losses (including other-than-temporary impairment charges); (xvi) our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition; (xvii) our ability to generate sufficient liquidity to meet our debt service obligations and other cash needs; (xviii) changes in capital deployment opportunities; (xix) our ability to maintain effective controls over financial reporting; (xx) our ability to continue to recruit and retain productive agents and distribution partners; (xxi) customer response to new products, distribution channels and marketing initiatives; (xxii) our ability to achieve additional upgrades of the financial strength ratings of CNO Financial and our insurance company subsidiaries as well as the impact of our ratings on our business, our ability to access capital and the cost of capital; (xxiii) regulatory changes or actions, including: those relating to regulation of the financial affairs of our insurance companies, such as the calculation of risk-based capital and minimum capital requirements, and payment of dividends and surplus debenture interest to us; regulation of the sale, underwriting and pricing of products; and health care regulation affecting health insurance products; (xxiv) changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products or affect the value of our deferred tax assets; (xxv) availability and effectiveness of reinsurance arrangements, as well as the impact of any defaults or failure of reinsurers to perform; (xxvi) the performance of third party service providers and potential difficulties arising from outsourcing arrangements; (xxvii) the growth rate of sales, collected premiums, annuity deposits and assets; (xxviii) interruption in telecommunication, information technology or other operational systems or failure to maintain the security, confidentiality or privacy of sensitive data on such systems; (xxix) events of terrorism, cyber attacks, natural disasters or other catastrophic events, including losses from a disease pandemic; (xxx) ineffectiveness of risk management policies and procedures in identifying, monitoring and managing risks; and (xxxi) the risk factors or uncertainties listed from time to time in our filings with the Securities and Exchange Commission. Other factors and assumptions not identified above are also relevant to the forward-looking statements, and if they prove incorrect, could also cause actual results to differ materially from those projected. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by the foregoing cautionary statement. Our forward-looking statements speak only as of the date made. We assume no obligation to update or to publicly announce the results of any revisions to any of the forward-looking statements to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements.

SOURCE CNO Financial Group, Inc.

For further information: (News Media) Valerie Dolenga, +1.312.396.7688, or (Investors) Jennifer Childe, +1.312.396.7755